Shivalik Rasayan Limited

Shivalik Rasayan Limited

SHIVALIK.NS
Shivalik Rasayan LimitedIN flagNational Stock Exchange of India
223.67
INR
+4.31
- -
3.52BMarket Cap
Shivalik Rasayan Limited
SHIVALIK.NS
(National Stock Exchange of India)

Recent

price

223.67

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
48.3
128.5
144.33
147.47
148.13
135.13
141.89
146.43
161.49
178.37
197.94
233.79
233.62
Revenue per Share
2.11
3.68
6.39
8.63
11.82
10.16
12.77
18.12
14.32
8.35
10.6
7.71
7.53
Basic EPS, GAAP
3.55
11.19
6.07
-21.02
-31.79
-61.38
-4.71
-9.79
-56.72
-49.75
-20.22
-32.18
- -
Free Cash Flow per Basic Share
- -
- -
- -
1.38
0.46
1.49
0.68
0.49
1.37
1.32
1.3
1.36
- -
Dividend per Share
4
4
4
26.89
36.13
39.74
52.27
68.5
86.63
93.94
102.84
5
5
Book Value per Share
13.15
17.95
30.79
89.42
190.49
180.83
188.11
257.76
288.75
332.86
339.97
380.25
379.97
Tangible Book Value per Share
9
9
9
11
12
14
14
14
14
15
16
16
16
Basic Weighted Avg Shares
413
1,099
1,234
1,551
1,705
1,863
1,956
2,070
2,340
2,715
3,118
3,680
3,680
Sales/Revenue/Turnover
6.43
7.62
13.06
14.03
12.2
13.91
16.32
18.98
14.13
10.98
7.84
7.34
7.33
Operating Margin (%)
2
23
23
24
-1
35
86
110
116
46
156
188
188
Depreciation Expense
18
32
55
91
136
140
176
256
207
127
167
121
119
Net Income, GAAP
33.66
32.99
25.15
24.78
19.99
17.42
14.74
7.31
5.78
22.13
12.75
16.33
16.33
Effective Tax Rate (%)
4.38
2.87
4.43
5.85
7.98
7.52
9
12.37
8.87
4.68
5.36
3.3
3.22
Profit Margin (%)
31
-15
85
574
1,503
829
400
1,267
1,180
1,355
1,364
1,919
1,919
Working Capital
2
113
116
66
54
26
111
84
130
240
165
262
262
LT Debt
112
154
263
944
2,197
2,495
2,595
3,647
4,193
5,076
5,362
5,991
5,991
Total Equity
- -
19.49
23.24
18.77
9.34
8.54
9.76
10.15
6.78
4.21
3.39
3.3
3.3
Return on Invested Capital (%)
- -
30.36
14.48
7.79
7.47
5.62
7.37
9.68
6.11
4.09
5.75
5.63
5.42
Return on Capital (%)
- -
92.11
159.79
57.29
38.94
29.06
27.76
30.33
18.66
9.47
10.95
14.29
13.97
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
791
- -
875
LT Borrowings
213
- -
262
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
16
- -
16
Market Capitalization
6,869
5,590
3,469

Working Capital

FRC

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
3,714
- -
3,821
Cash, Cash Equivalents & STI
468
- -
344
Accounts Receivable, Net
1,123
- -
1,151
Inventories
1,305
- -
1,469
Total Current Liabilities
1,923
- -
1,902
Payables & Accruals
- -
- -
- -
ST Debt
791
- -
875
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
57.39%
18.79%
11.72%
Free Cash Flow
13.25%
120.09%
59.08%
Net Income, GAAP
20.99%
-1.64%
-27.31%
Sales/Revenue/Turnover
13%
13.56%
18.04%
Total Cash Common Dividend
- -
33.99%
4.6%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
645
670
702
698
2,715
2025
746
824
853
694
3,118
2026
893
938
820
1,028
3,680

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.88
1.26
2.03
- -
8.35
2025
2.27
2.58
3.39
2.62
10.6
2026
1.02
1.93
1.71
2.87
7.71

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.32
2025
- -
- -
- -
- -
1.3
2026
- -
- -
- -
- -
1.36
Business
Shivalik Rasayan Limited is an Indian manufacturer specializing in organophosphorus-based agrochemicals and active pharmaceutical ingredients (API). The company produces a range of products including Dimethoate Technical, Malathion Technical, and other organophosphorus insecticides and chemicals that are used for plant protection. Its pharmaceutical segment focuses on the development and production of oncology and non-oncology APIs as well as finished dosage forms. The company operates primarily in India with a growing presence in international markets including Africa, Latin America, Far-East and CIS countries through its subsidiary Medicamen Biotech Limited. Founded in 1979 and headquartered in New Delhi, Shivalik Rasayan has recently expanded its capabilities by acquiring Medicamen Biotech Limited, establishing a state-of-the-art R&D center recognized by the Government of India for API development, and setting up a new agrochemical and synthetic organic chemicals plant at Dahej, which is expected to be operational by 2023. These strategic moves signify a shift towards integrated pharmaceutical manufacturing alongside its well-established agrochemical portfolio. The company serves diverse customer segments across agriculture and healthcare industries, delivering high-quality technical chemicals and pharmaceutical ingredients. This description encapsulates Shivalik Rasayan Limited's core product offerings, recent strategic expansions including acquisitions and facility upgrades, industry focus, geographic reach, and foundational background.